Supernus Pharmaceuticals Inc (SUPN) : Harbourvest Partners reduced its stake in Supernus Pharmaceuticals Inc by 62.58% during the most recent quarter end. The investment management company now holds a total of 103,192 shares of Supernus Pharmaceuticals Inc which is valued at $2,340,395 after selling 172,561 shares in Supernus Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Supernus Pharmaceuticals Inc makes up approximately 1.04% of Harbourvest Partners’s portfolio.
Other Hedge Funds, Including , Voya Investment Management reduced its stake in SUPN by selling 25,788 shares or 55.8% in the most recent quarter. The Hedge Fund company now holds 20,431 shares of SUPN which is valued at $463,375.Riverhead Capital Management reduced its stake in SUPN by selling 6,966 shares or 76.18% in the most recent quarter. The Hedge Fund company now holds 2,178 shares of SUPN which is valued at $49,397.Pacad Investment Ltd. reduced its stake in SUPN by selling 49,600 shares or 73.49% in the most recent quarter. The Hedge Fund company now holds 17,891 shares of SUPN which is valued at $405,768. Supernus Pharmaceuticals Inc makes up approx 0.05% of Pacad Investment Ltd.’s portfolio.
Supernus Pharmaceuticals Inc opened for trading at $21.47 and hit $22.12 on the upside on Thursday, eventually ending the session at $22.03, with a gain of 3.04% or 0.65 points. The heightened volatility saw the trading volume jump to 4,90,556 shares. Company has a market cap of $1,091 M.
On the company’s financial health, Supernus Pharmaceuticals Inc reported $0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.13. The company had revenue of $50.40 million for the quarter, compared to analysts expectations of $49.71 million. The company’s revenue was up 43.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
Many Wall Street Analysts have commented on Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 18, 2016. Supernus Pharmaceuticals Inc was Downgraded by Northland Capital to ” Market Perform” on Jul 18, 2016.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.